09:00 Feng XU,Chief IP Consultant and the Assistant Vice President of China & Asia Region, AstraZeneca 09:35 Wenyi PENG,Former Judge, Beijing Intellectual Property Court; Arbitrator of the Beijing Arbitration Commission, and Mediator of the Beijing Sunshine Intellectual Property Mediation Center 10:10 10:45 Coffee Break 11:15 Wenjun GENG,Vice President, CTTQ PHARMA 11:50 Tina TAI,Co-Head of Patent, King & Wood Mallesons Wenqiang ZHOU,Senior Patent Manager, Roche Cong YAO,Executive Director and Head of IP, Innovent Changgang LOU,Head of IP, Takeda (China) 12:40 Lunch 14:00 Wei CHEN,Former Director of Reexamination and Invalidation Department, CNIPA 14:35 Richard T. Ruzich,Partner, Taft Stettinius & Hollister Ian Scott,Partner, Taft Stettinius & Hollister 15:10 15:45 Tea Break 16:15 Lifang SUN,Vice President of Intellectual Property Department, Luye Pharma Group 16:50 Moderator: Huadong TANG,Partner, Merits & Tree Law Offices Tommy LIN,Vice President, Board Secretary and Director of IP and BD, HEC Pharma Ming WU,VP for Business Development Dept.,TYK Medicines Xiaojun LIAO,Senior IP Director, Legend Biotech 18:00 Round Table Dinner Development Trends of Pharmaceutical Intellectual Property Protection and Impact on the Industry Invalidating Strategies for Generic Drugs Under Chinese Patent Linkage Round Table: IP Management of Chinese Innovative Drugs License-out Updates on Patent Term Extension in China Key Issues and Adjudication Thoughts in Patent Linkage Disputes Round Table: Drug Application and Market Entry Strategies under the Patent Term Extension System Case Analysis of Pharmaceutical Patent Invalidation in China Invalidity Strategies in the US for Chinese Pharmaceutical Companies Practical Approaches and Case Analysis for Handling Overseas Intellectual Property Disputes EPO Updates on Patent Protection in Pharmaceutical Field 09:00 Wuzong ZENG,Level ⅠExaminer, CNIPA 09:35 10:10 10:45 Tea Break 11:10 Lu HUANG,Master Supervisor & Senior Engineer, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology 11:45 12:30 Closing of Sub-forum A & Lunch Evaluation of innovation level in protection topics such as drug crystals Global IP Portfolio Strategy for Domestic Pharmaceutical Companies Topic to Be Determined Global Patent Layout Strategies of Multinational Pharmaceutical Companies Topic to Be Determined |